0M40 Stock Overview
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Zynerba Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.31 |
| 52 Week High | US$1.40 |
| 52 Week Low | US$0.31 |
| Beta | 1.19 |
| 1 Month Change | -1.21% |
| 3 Month Change | 276.19% |
| 1 Year Change | 65.74% |
| 3 Year Change | n/a |
| 5 Year Change | -82.55% |
| Change since IPO | -89.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0M40 | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 4.0% | -1.3% | -0.9% |
| 1Y | 65.7% | -5.5% | -1.8% |
Return vs Industry: 0M40 exceeded the UK Pharmaceuticals industry which returned -7.1% over the past year.
Return vs Market: 0M40 exceeded the UK Market which returned -2.5% over the past year.
Price Volatility
| 0M40 volatility | |
|---|---|
| 0M40 Average Weekly Movement | 89.3% |
| Pharmaceuticals Industry Average Movement | 8.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0M40's share price has been volatile over the past 3 months.
Volatility Over Time: 0M40's weekly volatility has increased from 59% to 89% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 26 | Armando Anido | www.zynerba.com |
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery.
Zynerba Pharmaceuticals, Inc. Fundamentals Summary
| 0M40 fundamental statistics | |
|---|---|
| Market cap | US$65.60m |
| Earnings (TTM) | -US$37.58m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs 0M40 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0M40 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$37.58m |
| Earnings | -US$37.58m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0M40 perform over the long term?
See historical performance and comparison